On April 16, 2026 Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing therapeutics targeting metalloenzymes, reported the company will present data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5′ DNA flaps during replication and repair, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22 at the San Diego Convention Center, San Diego, CA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentation are as follows:
Abstract Number: 234
Title: "Proteomic profiling of FEN1 inhibition by BSM-1516 reveals chromatin-associated biomarkers for preclinical pharmacodynamic evaluation"
Session Title: DNA Damage and Repair 1
Session Date and Time: Sunday April 19, 2026 2:00 PM – 5:00 PM
Location: Poster Section 11
Poster Board Number: 5
The abstract is now available on the conference website at AACR (Free AACR Whitepaper) Annual Meeting 2026.
About FEN1
Flap endonuclease 1 (FEN1) is a structure-specific di-magnesium metallonuclease that cleaves 5′ DNA flaps during replication and repair. FEN1 is an attractive target for development of anticancer therapeutics because it is overexpressed in many tumor types and has a large number of synthetic lethality partners including genes in Homologous Recombination (HR) pathway.
About metalloenzymes and the Blacksmith platform
Metalloenzymes rely on metal ion cofactors within their active sites to perform critical biological functions. Historically, these targets have been challenging to drug due to limitations in small-molecule chemistry. The Blacksmith platform addresses these challenges through:
A proprietary fragment library of metal-binding pharmacophores (MBPs);
A comprehensive database mapping metalloenzyme functions, metal cofactors, and disease associations;
A unique metallo-CRISPR library of custom single guide RNAs;
An advanced computational toolkit for docking, modeling, and structure-based drug design;
A robust intellectual property portfolio spanning bioinorganic, medicinal, and computational chemistry for metalloenzyme-targeted therapeutics
(Press release, Blacksmith Medicines, APR 16, 2026, View Source [SID1234664431])